Please login to the form below

Not currently logged in
Email:
Password:

Alexion

This page shows the latest Alexion news and features for those working in and with pharma, biotech and healthcare.

AZ sells stake in Moderna for around $1.2bn

AZ sells stake in Moderna for around $1.2bn

AZ is looking to close its proposed acquisition of Alexion Pharmaceuticals, announced last year, in the third quarter of 2021.

Latest news

  • AZ forecasts growth in 2021 after revenues surge in Q4 AZ forecasts growth in 2021 after revenues surge in Q4

    AZ entered into a definitive agreement to purchase Alexion for $39bn in December 2020, in a bid to bolster and diversify AZ's drug portfolio with rare disease assets, and the ... The consistent achievements in the pipeline, the accelerating performance

  • Novartis receives FDA breakthrough therapy designation for rare disease med Novartis receives FDA breakthrough therapy designation for rare disease med

    If approved under the accelerated pathway, Novartis is likely to compete with Alexion’s C5-targeting therapy Soliris (eculizumab), which became the first treatment for all patients with PNH and atypical ... Alexion’s other long-acting C5 inhibitor,

  • AstraZeneca to acquire Alexion for $39bn AstraZeneca to acquire Alexion for $39bn

    The deal means AZ will immediately gain assets within Alexion’s commercial portfolio, estimated to be worth around $6bn. ... Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases

  • Roche’s Soliris rival Enspryng bags FDA approval Roche’s Soliris rival Enspryng bags FDA approval

    Roche’s neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng has scored US Food and Drug Administration (FDA) approval, setting up a market clash with Alexion’s Soliris. ... The first approved treatment in the US for NMOSD is Alexion’s

  • BMS pledges $300m to tackle health inequity and improve diversity BMS pledges $300m to tackle health inequity and improve diversity

    Earlier this month, Alexion Pharmaceuticals appointed its first chief diversity officer, with Uzair Qadeer taking on the role after serving as head of enterprise partnerships at the company.

More from news
Approximately 34 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Prior to CRISPR, he worked as head of translational medicine at Alexion Pharmaceuticals, and also served as chief medical officer of Taligen Therapeutics.

  • Abeona Therapeutics names CEO Abeona Therapeutics names CEO

    Carsten Thiel joins the biopharma from Alexion. Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel. ... Formerly serving as Alexion Pharmaceutical’s executive vice president and

  • Amryt Pharma appoints Jordi Casals as head of Europe Amryt Pharma appoints Jordi Casals as head of Europe

    Prior to this, he worked for eight years at Alexion Pharmaceuticals, latterly as vice president commercial operations, Western Europe.

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to

More from appointments
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • EPG Health EPG Health

    Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,

  • Mind+Matter Mind+Matter

    Our clients span the full spectrum of health – from deep pharma, to consumer health, healthy beauty and animal health.  They include: Aerogen,  Akcea,  Allakos, Alexion,  Amylyx Pharmaceuticals, Astellas, Baxter Healthcare, Bayer,

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics